


Table of Contents

1	Summary	
1.1	English	p. 4
1.2	Russian (Русский)	p. 5
2	Commentary	
2.1	European Union and West (EU & West)	p. 7
2.2	Balkans	p. 9
2.3	East	p. 10
2.4	TB mortality	p. 12
2.5	Conclusions & Recommendations	p. 12
2.6	References	p. 13
3	Tables	
	Summary Table. Tuberculosis surveillance data by area, 2005	p. 15
	Tuberculosis case reporting	
	Table 1 Tuberculosis cases, case rates per 100,000 population and mean annual change in rates, 2001-2005	p. 16
	Table 2 Tuberculosis cases by geographic origin and sex ratio, 2005	p. 17
	Table 3 Tuberculosis cases of national origin, by age group, 2005	p. 18
	Table 4 Tuberculosis cases of foreign origin, by age group, 2005	p. 19
	Table 5 Tuberculosis cases of foreign origin, by area of origin, 2005	p. 20
	Table 6 Tuberculosis cases by geographic origin, EU & West, 2000-2005	p. 21
	Table 7 Tuberculosis cases by site of disease, 2005	p. 22
	Table 8 Tuberculosis cases by area of origin and site of disease, 2005	p. 23
	Table 9 Paediatric and adult cases with TB meningitis or disseminated TB, by origin, 2005	p. 24
	Table 10 Extrapulmonary TB cases and pulmonary-to-extrapulmonary ratio, 1999-2005	p. 25
	Table 11 Pulmonary smear positive tuberculosis cases, 1999-2005	p. 26
	Table 12 Tuberculosis cases by history of previous TB diagnosis or anti-TB treatment, 1999-2005	p. 27
	Table 13 Tuberculosis cases confirmed by culture, 1999-2005	p. 28
	Table 14 Tuberculosis cases by <i>M. tuberculosis</i> complex species, 2005	p. 29
	Table 15 Tuberculosis cases with HIV infection, 2000-2005	p. 30
	Table 16 AIDS cases with tuberculosis as initial AIDS indicative disease, 2005	p. 31
	Table 17 AIDS cases with tuberculosis as initial AIDS indicative disease, by year of diagnosis, 2000-2005	p. 32
	Anti-tuberculosis drug resistance	
	Table 18 Multidrug resistance (MDR) by previous anti-TB treatment history, latest available data	p. 33
	Table 19 Laboratory practices and quality assurance for anti-TB drug susceptibility testing, 2005	p. 34
	Table 20 Characteristics of anti-TB drug resistance surveillance, 2005	p. 35
	Table 21 Anti-TB drug resistance, all tuberculosis cases (combined resistance), 2005	p. 36
	Table 22 Anti-TB drug resistance, previously untreated tuberculosis cases (primary resistance), 2005	p. 37
	Table 23 Combined anti-TB drug resistance, tuberculosis cases of national origin, 2005	p. 38
	Table 24 Combined anti-TB drug resistance, tuberculosis cases of foreign origin, 2005	p. 39
	Table 25 Combined multidrug resistance (MDR) by geographic origin, 2001-2005	p. 40
	Treatment outcome and mortality	
	Table 26 Characteristics of treatment outcome monitoring and treatment success, 2004	p. 41
	Table 27 Treatment outcomes, new definite pulmonary tuberculosis cases, 2004	p. 42
	Table 28 Treatment outcome, retreated definite pulmonary tuberculosis cases, 2004	p. 43
	Table 29 Treatment outcomes by geographic origin, all pulmonary cases, 2004	p. 44
	Table 30 Treatment outcomes by site of disease, 2004	p. 45
	Table 31 Tuberculosis deaths and mortality rates, 2000-2004	p. 46
	Table 32 Tuberculosis deaths by localisation of disease, latest available year	p. 47
4	Figures	
	Figure 1 TB notification rates, 2005	p. 49
	Figure 2 TB mortality rates, 2002-2004	p. 49
	Figure 3 Total TB notifications by previous treatment history and rates, 2001-2005	p. 50
	Figure 4 Mean annual percentage change in TB notification rates by area, 1995-2005	p. 51
	Figure 5 Tuberculosis cases by geographic origin, EU & West, 2000-2005	p. 51
	Figure 6 Multidrug resistance among previously untreated TB cases (primary MDR), 2005	p. 52
	Figure 7 Treatment outcome by age-group, previously untreated culture positive pulmonary TB cases, EU & West, 2004	p. 53
	Figure 8 Treatment outcomes by area, previously untreated definite pulmonary TB cases, 2001-2004	p. 53
5	Country Profiles	p. 55
6	Technical Note	p. 109

SURVEILLANCE OF TUBERCULOSIS IN EUROPE

Report on tuberculosis cases notified in 2005



EuroTB



WHO Collaborating Centre
for the Surveillance of
Tuberculosis in Europe



EuroTB national Contact Points and participating institutions (2006)

Country	Contact Points	Institution
Andorra	M. Coll Armangué	Ministry of Health and Welfare, Andorra la Vella
Albania	H. Hafizi	University Hospital of Lung Diseases, Tirana
Armenia	V. Pogosian	Ministry of Health, Yerevan
Austria	J.P. Klein	Federal Ministry for Health and Women, Vienna
Azerbaijan	S. Mammedova	Scientific Research Institute for Pulmonary Diseases, Baku
Belarus	H. Gurevich	Institute of Pulmonology and Phthisiatry, Minsk
Belgium	A. Aerts, M. Wanlin, G. Vankersschaever	Belgium Lung & Tuberculosis Association (BELTA), Brussels
Bosnia & Herzegovina	Z. Dizdarevic M. Duronjic	Clinic of Pulmonary Diseases and Tuberculosis "Podhrastovi", Sarajevo Ministry of Health and Social Security, Banja Luka
Bulgaria	D. Stefanova	TB University Clinic, Sofia
Croatia	A. Simunovic	Croatian National Institute of Public Health, Zagreb
Cyprus	P. Constantinou	Medical & Public Health Services, Nicosia
Czech Republic	L. Trnka, J. Wallenfels	National Tuberculosis Surveillance Unit, Prague
Denmark	P. Andersen	Statens Serum Institute, Copenhagen
Estonia	V. Hollo	Estonian National TB Register, Tallinn
Finland	P. Ruutu	National Public Health Institute, Helsinki
France	D. Che	Institut de Veille Sanitaire, Saint-Maurice
Georgia	A. Salakaia	National Centre for Tuberculosis and Lung Diseases, Tbilisi
Germany	B. Brodhun, W. Haas	Robert Koch-Institut, Berlin
Greece	G. Spala	National Centre for Surveillance and Intervention (NCSI), Athens
Hungary	G. Kovacs	"Koranyi" National Institute of Tuberculosis & Pulmonology, Budapest
Iceland	T. Blöndal	Health Care Services, Department of TB and Lung Diseases, Reykjavik
Ireland	J. O'Donnell	HSE Health Protection Surveillance Centre, Dublin
Israel	D. Chemtob	Ministry of Health, Jerusalem
Italy	M.G Pompa	Ministry of Health, Rome
Kazakhstan	G.B. Rakishev	Kazakh Tuberculosis Research Institute, Almaty
Kyrgyzstan	A S. Alisherov	National Tuberculosis & Lung Diseases Institute, Bishkek
Latvia	J. Leimans	State Centre of Tuberculosis & Lung Diseases of Latvia, Riga
Lithuania	E. Davidaviciene	Lithuanian Centre of Pulmonology & Tuberculosis, Vilnius
Luxembourg	P. Huberty-Krau	Directorate General of Health, Luxembourg
Macedonia, FYR	A. Videvska, S. Talevski	Institute for Lung Diseases and Tuberculosis, Skopje
Malta	A. Pace Ascjak	Department of Public Health, Qormi
Moldova, Republic of	S. Sofronie	Institute of Phthisiopulmonology, Chisinau
Monaco	A. Nègre	Direction de l'Action Sanitaire et Sociale, Monaco
Montenegro	O. Bojovic	Hospital for pulmonary diseases and TB, Niksic
Netherlands	C. Erkens	KNCV Tuberculosis Foundation, The Hague
Norway	B. Winje-Askeland	National Tuberculosis Register, Oslo
Poland	M. Korzeniewska-Kosela	National Tuberculosis & Lung Diseases Institute, Warsaw
Portugal	A. Fonseca Antunes	Ministry of Health, Directorate General of Health, Lisbon
Romania	E. Ibraim	Pneumology Institute "Marius Nasta" UIP, Bucharest
Russian Federation	E.P. Kakorina	Federal Ministry of Health and Social Development, Moscow
San Marino	A. Sorcinelli	State Hospital of San Marino, Cailungo
Serbia	G. Radosavljevic-Asic	Institute for Lung Diseases and Tuberculosis, Belgrade
Slovakia	I. Solovic	Institute for TB, Respiratory Diseases & Thoracic Surgery, Vysné Hagy
Slovenia	J. Sorli, D. Erzen	University Clinic of Respiratory and Allergic Diseases, Golnik
Spain	E. Rodriguez Valin	Institute of Health "Carlos III", Madrid
Sweden	V. Romanus	Swedish Institute for Infectious Disease Control, Solna
Switzerland	P. Helbling	Swiss Federal Office of Public Health, Bern
Tajikistan	S.M. Saidaliev	Tajikistan Medical University, Department of Tuberculosis, Dushanbe
Turkey	F. Gümüslü	Ministry of Health, Ankara
Turkmenistan	B. D. Jumaev	Central Hospital for Tuberculosis, Ashkhabad
Ukraine	M. Golubchikov	Centre of Medical Statistics, Ministry of Health, Kiev
United Kingdom	J. Watson J. McMenamin R. Salmon	Health Protection Agency, London Health Protection Scotland, Glasgow National Public Health Service, CDSC, Cardiff, Wales
Uzbekistan	B. Smyth A. Yuldashev	Communicable Disease Surveillance Centre, Northern Ireland, Belfast Scientific Research Institute of Phthisiology and Pulmonology, Tashkent

EuroTB is a European network for surveillance of tuberculosis in Europe set up in 1996, based on the participation of the national tuberculosis surveillance institutions in the 53 countries of the WHO European Region. The network is coordinated at the Institut de Veille Sanitaire (InVS), France, and is financially supported by the European Commission (DG-SANCO). EuroTB aims to improve the contribution of surveillance to tuberculosis control in the WHO European region, through the provision of valid, comparable epidemiological information on tuberculosis.

"Surveillance of tuberculosis in Europe" is the annual report prepared by the EuroTB project staff. Printed copies can be requested at the address below. The electronic version of the report is accessible via the project website www.eurotb.org.

The suggested citation for the report is the following:

i) English

EuroTB and the national coordinators for tuberculosis surveillance in the WHO European Region. Surveillance of tuberculosis in Europe. Report on tuberculosis cases notified in 2005, Institut de veille sanitaire, Saint-Maurice, France. March 2007

ii) Russian (Русский)

ЕвроТБ и национальные координаторы по эпиднадзору за туберкулезом в Европейском регионе ВОЗ. Эпиднадзор за туберкулезом в Европе. Доклад о случаях туберкулеза, зарегистрированных в 2005 г., Институт по контролю здоровья, Сен Морис, Франция. Март 2007 г.

Acknowledgements

Data collection and validation of aggregate data on TB case notification and treatment outcome monitoring were done jointly with TB control staff at the WHO-Regional Office for Europe (Richard Zaleskis) and at the WHO Headquarters (Christopher Dye, Mehran Hosseini). The European AIDS reporting data set (ENAADS), including data on tuberculosis as initial AIDS indicative disease, was provided by the project "Surveillance of HIV/AIDS in Europe" (EuroHIV). The Advisory Committee of EuroTB has provided support and advice, including on the production of this report. Current members are: Luke Clancy (UNION), Francis Drobniewski (United Kingdom), Michael Forssbohm (Germany), Elmira Ibraim (Romania), Jean-Paul Klein (Austria), Maria Korzeniewska-Kosela (Poland), Vincent Kuyvenhoven (KNCV), Petri Ruutu (Finland), John Watson (United Kingdom), and Richard Zaleskis (WHO-EURO). The European Centre for Disease Prevention and Control (ECDC) attended Committee meetings in 2006.

EuroTB staff (2006-7)

Fatima AÏT-BELGHITI	epidemiologist
Hedwige BOUSQUIÉ	assistant
Isabelle DEVAUX	epidemiologist
Dennis FALZON	programme coordinator

Neither the European Commission nor any person acting on behalf of the Commission is liable for the use that may be made of the information contained in this report. Maps and commentary used in this report do not imply any opinion whatsoever of EuroTB or its partners on the legal status of the countries and territories shown or concerning their borders.

EuroTB – Institut de Veille Sanitaire
12, rue du Val d'Osne - 94415 Saint-Maurice Cedex - France
Telephone: +33.1.41.79.68.05 Fax: + 33.1.41.79.68.02
e-mail: eurotb@invs.sante.fr Internet: www.eurotb.org